Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

522
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
522
Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

1.5K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
1.5K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

697
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
697
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

696
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
696
Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

1.2K
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same author

Facilitators and barriers to blood and blood product accessibility and use in sub-Saharan Africa: a systematic review.

Frontiers in health services·2026
Same author

Development and Validation of an Artificial Intelligence Tool for Automated Population, Intervention, Comparator, Outcome Scoping for the European Joint Clinical Assessment: A Proof of Concept.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Evaluation of standardized DICOM labels assigned by a hybrid AI tool and its impact on radiologists' reading times.

European radiology·2026
Same author

EU-HTA-Why Do Words Matter?

Journal of market access & health policy·2026
Same author

Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials.

The Lancet. Oncology·2026

Related Experiment Video

Updated: Mar 20, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K

Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges.

Hans-Joerg Fugel1, Mark Nuijten2, Maarten Postma1

  • 1Department of Pharmacy, University of Gronigen Groningen, Netherlands.

Frontiers in Pharmacology
|June 1, 2016
PubMed
Summary

Stratified Medicine (SM) requires new health economic (HE) evaluation guidelines. Current methods face challenges in comparing treatments, measuring outcomes, and modeling complex interventions for patient subgroups.

Keywords:
biomarkersguidelineshealth technology assessmentsreimbursementreimbursement mechanismsstratified medicine

Related Experiment Videos

Last Updated: Mar 20, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Biomarker-driven Therapies

Background:

  • Stratified Medicine (SM) utilizes biomarkers to target therapies to specific patient populations.
  • Economic evaluations are crucial for reimbursement decisions but existing guidelines were developed for traditional pharmaceuticals.
  • The complexity of SM interventions necessitates evaluating the adequacy of current health economic (HE) guidelines.

Purpose of the Study:

  • To identify specific methodological challenges in conducting HE evaluations for SM interventions.
  • To propose modifications to existing HE guidelines for consistent economic assessments in SM.

Main Methods:

  • Review of existing health economic evaluation guidelines.
  • Analysis of methodological challenges specific to Stratified Medicine.

Main Results:

  • Key challenges include comparator selection, effectiveness and outcome measurement, and appropriate modeling structures.
  • Sensitivity analyses require specific considerations for SM.

Conclusions:

  • Current HE methodology can be adapted for SM, but requires further development.
  • Modifications to existing guidelines are necessary to address the complexities of SM and ensure consistent economic evaluations.